Cancer Family
Pancreaticobiliary Neoplasm
CI-CAN-00000309Explore in graph →
Non-malignant1,204 active trials11 approved drugs92 evidence items
- NCIt
- C223357
Loading cancer entity…
Cancer Family
CI-CAN-00000309Explore in graph →
Clinical trials
5,004 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05914077 | Aspiration of Duodenopancreatic Juice After Secretin Stimulation vs Endoscopic Aspiration for Molecular Analysis of Intraductal Papillary Mucinous Intraductal Neoplasia.(RESCUE) | unknown | Phase 3 | 140 | Fundacion Clinic per a la Recerca BiomédicaOTHER | 1 | Sep 18, 2023 | clinicaltrials |
| NCT06013943 | Envafolimab Combined With GEMOX in First-line Treatment of Advanced GBC | unknown | Phase 2 | 30 | Eastern Hepatobiliary Surgery HospitalOTHER | 1 |
| Sep 15, 2023 |
| clinicaltrials |
| NCT05907824 | Long-term Prognosis for Non-functional Neuroendocrine Tumors of the Pancreatic Body and Tail ≤ 3cm | unknown | — | 800 | Fudan UniversityOTHER | 1 | Sep 13, 2023 | clinicaltrials |
| NCT05271344 | Oral Immunonutrition With Synbiotics, Omega 3 and Vitamin D in Patients Undergoing Duodenopancreatectomy for Tumoral Lesion.(SIO3D) | unknown | N/A | 74 | Centre Hospitalier Universitaire de LiegeOTHER | 1 | Sep 11, 2023 | clinicaltrials |
| NCT03777462 | Borderline Resectable Pancreatic Cancer Neoadjuvant Chemoradiotherapy Clinicaltrial-1(BRPCNCC-1) | unknown | Phase 2 | 150 | Changhai HospitalOTHER | 1 | Sep 1, 2023 | clinicaltrials |
| NCT04324307 | Study of Immunotherapy Combined With Chemotherapy in Locally Advanced and Metastatic Pancreatic Cancer | unknown | Phase 1 / Phase 2 | 60 | Changhai HospitalOTHER | 1 | Sep 1, 2023 | clinicaltrials |
| NCT04373928 | Personalized Precision Diagnosis and Treatment of Pancreatic Cancer(PPDTPC) | unknown | N/A | 100 | Changhai HospitalOTHER | 1 | Sep 1, 2023 | clinicaltrials |
| NCT04902261 | Tislelizumab Combined With Nab-paclitaxel and Gemcitabine for Recurrent Pancreatic Cancer | unknown | Phase 2 | 140 | Changhai HospitalOTHER | 1 | Sep 1, 2023 | clinicaltrials |
| NCT05783076 | SBRT Plus vNKT for Pancreatic Cancer | unknown | Phase 2 | 29 | Changhai HospitalOTHER | 1 | Aug 30, 2023 | clinicaltrials |
| NCT05681949 | Therapeutic Assistance and Decision-making Algorithms in Hepatobiliary Tumor Boards(ADBoard) | unknown | N/A | 1,200 | Charite University, Berlin, GermanyOTHER | 1 | Aug 24, 2023 | clinicaltrials |
| NCT05997147 | A Preoperative Model to Predict the Lymphovascular Invasion in Pancreatic Ductal Adenocarcinoma | unknown | — | 1,009 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Aug 18, 2023 | clinicaltrials |
| NCT05023109 | GP Chemotherapy in Combination With Anti-PD-1 and Anti-TIGIT in Unresectable Advanced BTC | unknown | Phase 2 | 45 | Shanghai Zhongshan HospitalOTHER | 1 | Aug 15, 2023 | clinicaltrials |
| NCT05233293 | Spyglass+RFA Versus Cytobrush+RFA for Extrahepatic Cholangiocarcinoma | unknown | N/A | 200 | First People's Hospital of HangzhouOTHER | 1 | Aug 15, 2023 | clinicaltrials |
| NCT05977777 | Contrast-enhanced Ultrasound and Pancreatic Lesions | unknown | N/A | 50 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Aug 4, 2023 | clinicaltrials |
| NCT05703581 | Application of "Heidelberg Triangle" Dissection in Pancreatoduodenectomy and Distal Pancreatectomy | unknown | — | 200 | Fudan UniversityOTHER | 1 | Aug 1, 2023 | clinicaltrials |
| NCT05959395 | Hyperthermia Treatment Added to Chemotherapy Standard of Care for Pancreatic Tumors | unknown | N/A | 5 | NeoTherma OncologyINDUSTRY | 1 | Jul 27, 2023 | clinicaltrials |
| NCT05957250 | [68Ga]Ga-FAPI-46 Positron Emission Tomography (PET) Scan to Improve the Imaging of Pancreatic and Bile Duct Cancer(PANSCAN-1) | unknown | N/A | 63 | Amsterdam UMC, location VUmcOTHER | 1 | Jul 24, 2023 | clinicaltrials |
| NCT05955092 | Exploring the Application of 3D Bioprinting for Personalized Treatment in Pancreatic Ductal Adenocarcinoma | unknown | — | 30 | Peking Union Medical College HospitalOTHER | 1 | Jul 21, 2023 | clinicaltrials |
| NCT05595122 | EUS-guided Choledochoduodenostomy for Primary Drainage of Malignant Distal Biliary Obstruction(SCORPION-II-p) | unknown | N/A | 25 | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)OTHER | 1 | Jul 20, 2023 | clinicaltrials |
| NCT04445532 | Hepatobiliary Tumors Tissue Samples Acquisition | unknown | — | 450 | Peking Union Medical College HospitalOTHER | 1 | Jul 7, 2023 | clinicaltrials |
| NCT05223218 | Investigating the Diagnostic Potential of Tear Proteins in Cancer - A Pilot Study | unknown | — | 500 | Namida LabINDUSTRY | 1 | Jul 3, 2023 | clinicaltrials |
| NCT05549960 | Pre-planning Mathematical Models in EUS-guided Laser Ablation of Pancreatic Lesions(LA-EUS MOD) | unknown | N/A | 10 | Campus Bio-Medico UniversityOTHER | 1 | Jul 3, 2023 | clinicaltrials |
| NCT05919095 | A Clinical Study of a Preoperative Translational Therapy for Unresectable Gallbladder Cancer | unknown | Phase 2 | 37 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Jun 26, 2023 | clinicaltrials |
| NCT04803851 | Anlotinib Plus Anti-PD-1 Antibody AK105 for Advanced Pancreatic Cancer | unknown | Phase 1 / Phase 2 | 29 | Peking Union Medical College HospitalOTHER | 1 | Jun 22, 2023 | clinicaltrials |
| NCT05911425 | Combined Treatment of Treated Bile Duct Cancer(CHOL) | unknown | Phase 2 | 30 | Zhejiang Cancer HospitalOTHER | 0 | Jun 22, 2023 | clinicaltrials |
| NCT05913661 | Pemigatinib Combined With PD-1 Inhibitor in Unresectable or Metastatic Intrahepatic Cholangiocarcinoma | unknown | Phase 2 | 30 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Jun 22, 2023 | clinicaltrials |
| NCT03809247 | Microbial Diversity of Pancreatic Diseases | unknown | — | 330 | Ruijin HospitalOTHER | 1 | Jun 15, 2023 | clinicaltrials |
| NCT05193162 | Retrospective Study on Microbial Diversity in Paraffin Tissue of Pancreatic Diseases | unknown | — | 800 | Ruijin HospitalOTHER | 1 | Jun 15, 2023 | clinicaltrials |
| NCT05681390 | Tislelizumab With Anlotinib and Chemotherapy for Second-line Treatment of Pancreatic Cancer | unknown | Phase 2 | 30 | First Affiliated Hospital Xi'an Jiaotong UniversityOTHER | 1 | Jun 9, 2023 | clinicaltrials |
| NCT05886075 | A Clinical Study on Oncolytic Virus Injection (R130) for the Treatment of Relapsed/Refractory Advanced Solid Tumors | unknown | Early Phase 1 | 24 | Shanghai Yunying Medical TechnologyINDUSTRY | 1 | Jun 2, 2023 | clinicaltrials |
| NCT05393986 | Claudin18.2-redirected Chimeric Antigen Receptor T Cells With Co-expression of Cytokines in Solid Tumors | unknown | Phase 1 | 63 | Peking UniversityOTHER | 1 | May 31, 2023 | clinicaltrials |
| NCT05754788 | Gene Expression Profile of Resected Pancreatic and Ampullary Adenocarcinoma at Favorable Prognosis | unknown | — | 40 | Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoOTHER | 1 | May 26, 2023 | clinicaltrials |
| NCT02745847 | Re-irradiation With Stereotactic Body Radiotherapy for Relapsed Pancreatic Cancer | unknown | N/A | 30 | Changhai HospitalOTHER | 1 | May 25, 2023 | clinicaltrials |
| NCT05875753 | 68Ga-FAPI-FS PET/CT and PET/MR in Pancreatic Cancer | unknown | Early Phase 1 | 50 | Peking Union Medical College HospitalOTHER | 1 | May 25, 2023 | clinicaltrials |
| NCT03820310 | Clinical Trial of Autologous Tcm Immunotherapy in ICC | unknown | Phase 2 | 20 | Newish Technology (Beijing) Co., Ltd.INDUSTRY | 1 | May 24, 2023 | clinicaltrials |
| NCT03553004 | Niraparib in Metastatic Pancreatic Cancer After Previous Chemotherapy (NIRA-PANC): a Phase 2 Trial(NIRA-PANC) | unknown | Phase 2 | 18 | University of Kansas Medical CenterOTHER | 1 | May 19, 2023 | clinicaltrials |
| NCT05860374 | A Clinical Study on Oncolytic Virus Injection (R130) for the Treatment of Advanced Solid Tumors | unknown | Early Phase 1 | 20 | Shanghai Yunying Medical TechnologyINDUSTRY | 1 | May 16, 2023 | clinicaltrials |
| NCT04855331 | Laparoscopic Versus Open Pancreatoduodenectomy Following Neoadjuvant Chemotherapy for BRPC | unknown | N/A | 120 | Fudan UniversityOTHER | 1 | May 9, 2023 | clinicaltrials |
| NCT05842187 | In Vitro Organoid Drug Sensitivity-Guided Treatment for Metastatic Pancreatic and Gastric Cancer(ODYSSEY) | unknown | N/A | 20 | Jianzhen Shan, MDOTHER | 1 | May 6, 2023 | clinicaltrials |
| NCT05669287 | Defining a Vascular Phenotype of Pancreatic Ductal Adenocarcinoma With CT Perfusion Using Quantitative Radiomics | unknown | N/A | 125 | Radboud University Medical CenterOTHER | 1 | May 3, 2023 | clinicaltrials |
| NCT05830019 | Carbon Ion Radiotherapy for Recurrent Pancreatic Cancer Post Surgery | unknown | N/A | 49 | Shanghai Proton and Heavy Ion CenterOTHER | 1 | Apr 26, 2023 | clinicaltrials |
| NCT05831488 | Assessing the Accuracy of Seismofit® as an Estimate of VO2 Peak in Patients With Hepato-pancreato-biliary, Colorectal, and Gastro-oesophageal Cancer(VERVE) | unknown | — | 35 | Royal Marsden NHS Foundation TrustOTHER | 1 | Apr 26, 2023 | clinicaltrials |
| NCT03558945 | Clinical Trial on Personalized Neoantigen Vaccine for Pancreatic Tumor | unknown | Phase 1 | 30 | Anda Biopharmaceutical Development (Shenzhen) Co., Ltd.INDUSTRY | 1 | Apr 24, 2023 | clinicaltrials |
| NCT05822453 | Gemcitabine Plus S1 and Tislelizumab in the First Line Therapy of Advanced Biliary Tract Carcinoma | unknown | Phase 2 | 20 | Peking Union Medical College HospitalOTHER | 1 | Apr 20, 2023 | clinicaltrials |
| NCT04164602 | The Occurence of Pancreatic Cancer Studied in Association With Newly Diagnosed Diabetes in the Elderly(NODES) | unknown | — | 2,522 | University of PecsOTHER | 1 | Apr 19, 2023 | clinicaltrials |
| NCT04454905 | Camrelizumab in Combination With Apatinib in Advanced ICC: A Single-arm Phase II Study | unknown | Phase 2 | 50 | Sun Yat-sen UniversityOTHER | 1 | Apr 19, 2023 | clinicaltrials |
| NCT05400902 | HAIC Combined With Sintilimab and Bevacizumab for Unresectable Intrahepatic Cholangiocarcinoma | unknown | Phase 2 | 17 | Binkui LiOTHER | 1 | Apr 13, 2023 | clinicaltrials |
| NCT05802420 | The Value of Molecular Residual Disease Monitoring Based on ctDNA in Advanced or Metastatic Pancreatic Cancer(MAP-01) | unknown | N/A | 100 | Peking Union Medical College HospitalOTHER | 1 | Apr 12, 2023 | clinicaltrials |
| NCT05805956 | IMM2902 in Patients With Advanced Solid Tumors Expressing HER2 | unknown | Phase 1 / Phase 2 | 105 | ImmuneOnco Biopharmaceuticals (Shanghai) Inc.OTHER | 1 | Apr 10, 2023 | clinicaltrials |
| NCT05795920 | Utidelone Injection Combined With Gemcitabine in First-line Chemotherapy for Unresectable Advanced Pancreatic Cancer | unknown | Phase 2 | 92 | Shanghai General Hospital, Shanghai Jiao Tong University School of MedicineOTHER | 1 | Apr 3, 2023 | clinicaltrials |
Data updated 23 days agoSource updated Sep 18, 2023source: clinicaltrials